GSK2654909A

GSK2654909A is an unadjuvanted, monovalent inactivated split-virion influenza vaccine candidate developed by GSK. It is designed to provide active immunity against the H9N2 subtype of Influenza A, an avian influenza virus identified as having significant pandemic potential. The vaccine is manufactured in Quebec, Canada, using a process involving embryonated chicken eggs. In clinical studies, GSK2654909A has been evaluated for safety, reactogenicity, and immunogenicity in adults, often serving as a baseline comparator to adjuvanted formulations (such as GSK2654911A) to determine the necessity and impact of adjuvant systems in achieving protective antibody titers against avian-origin influenza antigens.

Other names

monovalent H9N2 influenza vaccineH9N2 monovalent inactivated vaccineH-9N2 monovalent inactivated vaccineH 9N2 monovalent inactivated vaccineH9N2 vaccineH-9N2 vaccineH 9N2 vaccine